SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I
| Image |  |
|---|---|
| Description | scientific article published on 10 October 2016 |
| Author/s |
author: Swiss Group for Clinical Cancer Research Klazien Matter-Walstra Christoph Rochlitz Andreas Wicki |
| Publication date | October 10, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |